ARID1A
Basic information
Region (hg38): 1:26693236-26782104
Previous symbols: [ "C1orf4", "SMARCF1" ]
Links
Phenotypes
GenCC
Source:
- intellectual disability, autosomal dominant 14 (Strong), mode of inheritance: AD
- Coffin-Siris syndrome 1 (Definitive), mode of inheritance: AD
- intellectual disability, autosomal dominant 14 (Strong), mode of inheritance: AD
- Coffin-Siris syndrome (Supportive), mode of inheritance: AD
- Coffin-Siris syndrome (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Coffin-Siris syndrome 2 (Mental retardation, autosomal dominant 14) | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Dermatologic; Musculoskeletal; Neurologic | 22426308; 22426309 |
ClinVar
This is a list of variants' phenotypes submitted to
- Intellectual disability, autosomal dominant 14 (25 variants)
- not provided (13 variants)
- ARID1A-related BAFopathy (5 variants)
- Inborn genetic diseases (3 variants)
- ARID1A-related disorder (2 variants)
- Coffin-Siris syndrome 1 (2 variants)
- Malignant tumor of urinary bladder (1 variants)
- Non-immune hydrops fetalis (1 variants)
- Septo-optic dysplasia sequence (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ARID1A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 19 | 247 | 45 | 311 | ||
missense | 19 | 410 | 107 | 58 | 596 | |
nonsense | 25 | 29 | ||||
start loss | 2 | |||||
frameshift | 17 | 26 | ||||
inframe indel | 31 | 18 | 53 | |||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 2 | 9 | 14 | 3 | 28 | |
non coding | 62 | 26 | 91 | |||
Total | 46 | 35 | 466 | 434 | 131 |
Variants in ARID1A
This is a list of pathogenic ClinVar variants found in the ARID1A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-26695829-G-A | Likely benign (Apr 04, 2019) | |||
1-26695894-T-C | Likely benign (Nov 10, 2018) | |||
1-26696377-C-T | Benign (Mar 26, 2020) | |||
1-26696397-G-T | not specified | Uncertain significance (Jun 21, 2016) | ||
1-26696405-T-C | Uncertain significance (Aug 07, 2020) | |||
1-26696405-T-G | Uncertain significance (Sep 16, 2022) | |||
1-26696407-G-A | Uncertain significance (Jun 15, 2023) | |||
1-26696416-G-A | Uncertain significance (Aug 05, 2023) | |||
1-26696421-CCCCGCCGCCGCCAGCAGCCTGGGCAA-C | Intellectual disability, autosomal dominant 14 • Coffin-Siris syndrome 1 | Pathogenic (Apr 19, 2024) | ||
1-26696425-G-A | Uncertain significance (Jul 06, 2020) | |||
1-26696427-C-G | Likely benign (Jan 16, 2024) | |||
1-26696439-C-T | ARID1A-related disorder | Benign (Jan 12, 2024) | ||
1-26696441-T-G | Inborn genetic diseases | Uncertain significance (Jun 07, 2024) | ||
1-26696448-CCCG-C | ARID1A-related disorder | Likely benign (Sep 12, 2023) | ||
1-26696448-CCCGCCG-C | Likely benign (Jul 11, 2022) | |||
1-26696448-C-CCCG | not specified • Astrocytoma • Inborn genetic diseases • ARID1A-related disorder | Conflicting classifications of pathogenicity (Feb 01, 2024) | ||
1-26696448-C-CCCGCCG | Inborn genetic diseases • ARID1A-related disorder | Benign/Likely benign (Jan 11, 2024) | ||
1-26696458-C-G | Uncertain significance (Sep 01, 2019) | |||
1-26696463-G-A | Likely benign (Jan 01, 2023) | |||
1-26696469-G-C | Likely benign (May 04, 2021) | |||
1-26696470-G-T | ARID1A-related disorder | Conflicting classifications of pathogenicity (Jul 31, 2024) | ||
1-26696475-G-C | Likely benign (Aug 10, 2021) | |||
1-26696478-G-A | Benign (Jun 29, 2023) | |||
1-26696484-C-T | ARID1A-related disorder | Likely benign (Dec 14, 2020) | ||
1-26696494-C-G | Inborn genetic diseases | Uncertain significance (Sep 17, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ARID1A | protein_coding | protein_coding | ENST00000324856 | 20 | 86072 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.67e-13 | 125745 | 0 | 2 | 125747 | 0.00000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.66 | 823 | 1.18e+3 | 0.700 | 0.0000669 | 14782 |
Missense in Polyphen | 44 | 120.16 | 0.36619 | 1335 | ||
Synonymous | -1.27 | 494 | 459 | 1.08 | 0.0000269 | 4683 |
Loss of Function | 8.55 | 2 | 89.0 | 0.0225 | 0.00000473 | 980 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000289 | 0.0000289 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000879 | 0.00000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). {ECO:0000250|UniProtKB:A2BH40, ECO:0000303|PubMed:12672490, ECO:0000303|PubMed:22952240, ECO:0000303|PubMed:26601204}.;
- Pathway
- Thermogenesis - Homo sapiens (human);Hepatocellular carcinoma - Homo sapiens (human);miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Androgen Receptor Network in Prostate Cancer;Pathways Affected in Adenoid Cystic Carcinoma;Tumor suppressor activity of SMARCB1;Gene expression (Transcription);RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known;the information processing pathway at the ifn beta enhancer;Generic Transcription Pathway;RNA Polymerase II Transcription;RMTs methylate histone arginines;Chromatin modifying enzymes;Chromatin organization;chromatin remodeling by hswi/snf atp-dependent complexes;Transcriptional regulation by RUNX1
(Consensus)
Recessive Scores
- pRec
- 0.151
Intolerance Scores
- loftool
- 0.0215
- rvis_EVS
- -2.67
- rvis_percentile_EVS
- 0.74
Haploinsufficiency Scores
- pHI
- 0.549
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.683
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.942
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Arid1a
- Phenotype
- immune system phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hearing/vestibular/ear phenotype; vision/eye phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); neoplasm; embryo phenotype; homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;formation of primary germ layer;neural tube closure;cardiac chamber development;optic cup formation involved in camera-type eye development;nucleosome disassembly;chromatin remodeling;maintenance of chromatin silencing;regulation of transcription by RNA polymerase II;embryo implantation;stem cell population maintenance;intracellular estrogen receptor signaling pathway;androgen receptor signaling pathway;forebrain development;nucleosome mobilization;glucocorticoid receptor signaling pathway;ATP-dependent chromatin remodeling;positive regulation of transcription, DNA-templated;chromatin-mediated maintenance of transcription;cardiac muscle cell differentiation;placenta blood vessel development;toxin transport
- Cellular component
- nuclear chromatin;nucleus;nucleoplasm;SWI/SNF complex;npBAF complex;nBAF complex
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;transcription coactivator activity;protein binding;nuclear receptor binding;nucleosome binding